Halozyme Therapeutics Reports Q3 2026 Financial Results and Raises Full-Year Guidance

Halozyme Therapeutics reported third-quarter 2026 revenue of $493 million, up 39.2% year over year, including royalty revenue of $341 million, up 44%. Non-GAAP earnings were $2.39 per diluted share, exceeding analyst consensus. The company raised its 2026 guidance to revenue of $1.86 billion–$1.93 billion and non-GAAP diluted EPS of $8.75–$9.05.